News
Company News
The Journal of Clinical Oncology (JCO) Publishes Full Results of Disitamab Vedotin in a "Triple-Drug Combination" (RCTS) Regimen for First-Line Gastric Cancer Therapy
On June 27, the world-renowned oncology journal Journal of Clinical Oncology (JCO) published the full research paper from a Phase II RCTS trial online. The study evaluated the combination of Disitamab Vedotin, Tislelizumab, and S-1 as a first-line th
First Patient In Achieved in RemeGen’s Phase II/III Clinical Study of RC148 in Combination with Chemotherapy as First-Line Therapy for Unresectable or Metastatic Colorectal Cancer
OnJun 15th, RemeGen (688331.SH/09995.HK) announced that the first patient has been dosed in its Phase II/III clinical study of RC148 (RC148-C303), a novel bispecific antibody independently developed by RemeGen, in combination with chemotherapy as first-li
Remegen's Telitacicept Two Indications Approved on the Same Day, Patients with Sjögren's Syndrome (Dry Disease) and IgA Nephropathy Welcome the World's First Dual-Target Biologic Drug
On June 8, Remegen (688331.SH/09995.HK) announced that its self-developed global first-in-class BLyS/APRIL dual-target fusion protein innovative drug Telitacicept (RC18) has received approval from the China National Medical Products Administration (NMPA)
-
2026.06 28
The Journal of Clinical Oncology (JCO) Publishes Full Results of Disitamab Vedotin in a "Triple-Drug Combination" (RCTS) Regimen for First-Line Gastric Cancer Therapy
On June 27, the world-renowned oncology journal Journal of Clinical Oncology (JCO) published the full research paper from a Phase II RCTS trial online. The study evaluated the combination of Disitamab Vedotin, Tislelizumab, and S-1 as a first-line th
-
2026.06 15
First Patient In Achieved in RemeGen’s Phase II/III Clinical Study of RC148 in Combination with Chemotherapy as First-Line Therapy for Unresectable or Metastatic Colorectal Cancer
OnJun 15th, RemeGen (688331.SH/09995.HK) announced that the first patient has been dosed in its Phase II/III clinical study of RC148 (RC148-C303), a novel bispecific antibody independently developed by RemeGen, in combination with chemotherapy as first-li
-
2026.06 08
Remegen's Telitacicept Two Indications Approved on the Same Day, Patients with Sjögren's Syndrome (Dry Disease) and IgA Nephropathy Welcome the World's First Dual-Target Biologic Drug
On June 8, Remegen (688331.SH/09995.HK) announced that its self-developed global first-in-class BLyS/APRIL dual-target fusion protein innovative drug Telitacicept (RC18) has received approval from the China National Medical Products Administration (NMPA)
-
2026.04 17
2026 EAU | Original Research Findings on Disitamab Vedotin Unveiled: Showcasing Breakthroughs in Urothelial Carcinoma Care
The Annual European Association of Urology Congress 2026 (EAU Congress 2026), one of the world’s premier urological events, was held in London, the United Kingdom, from March 13 to 16, 2026 (UTC+0). At the congress, results of multiple researches
-
2026.02 28
2026 ASCO-GU | RC48-C017 study update: Disitamab vedotin plus immunotherapy as neoadjuvant treatment delivers lasting survival gains in bladder cancer.
On February 27 local time, at the 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO-GU) held in San Francisco, USA, the latest efficacy and safety data from the extended follow-up of the phase II clinical study (RC48-C017) o
-
2026.01 16
2026 JPM | Rongchang Biotech: Delivering Innovation at Scale, Solidifying Its Global Competitive Edge for the Future
On January 15 at 9:00 a.m. local time, Dr. Jianmin Fang, CEO of RemeGen, took the stage at the 44th J.P. Morgan Healthcare Conference in San Francisco—a premier global event for pharmaceutical innovation and investment trends. In his keynote address
-
2026.01 12
Remegen and AbbVie sign exclusive licensing agreement for RC148
On January 12, Rongchang Biopharmaceutical (Yantai) Co., Ltd. (688331.SH/09995.HK, hereinafter referred to as "Rongchang Bio") announced the signing of an exclusive licensing agreement with AbbVie Group Holdings (hereinafter referred to as "
-
2025.10 20
ESMO Congress 2025 Presidential Symposium Oral Presentation | Disitamab Vedotin Achieves Major Breakthrough as First-Line Treatment for Urothelial Carcinoma
BERLIN, Oct. 20, 2025 /PRNewswire/ -- At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally adv
-
2025.09 17
Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting
YANTAI, China, Sept. 17, 2025 /PRNewswire/ -- RemeGen (688331.SH/09995.HK) announced that the 48-week open-label extension (OLE) data from China Phase III clinical study of telitacicept (RC18, brand name: 泰爱®, a BLyS/APRIL dual-targ
-
2025.08 18
RemeGen and Santen Enter into Exclusive Licensing Agreement for Ophthalmic Innovative Drug RC28-E in Greater China and Asian countries
YANTAI, China, Aug. 18, 2025 /PRNewswire/ -- RemeGen Co., Ltd. (Stock Code: 688331.SH/09995.HK, "RemeGen"), a leading Chinese biopharmaceutical company, announced today that it has entered into an agreement with Santen Pharmaceuti
Press Release
-
RemeGen Co., Ltd. Announced New RC48-ADC Data in Patients with Advanced Gastric Cancer at ASCO
First patient enrolled in Telitacicept IgA nephropathy PhaseⅡclinical trial in the U.S.
more
No. 58 Beijing Middle Road, Yantai Development Zone, Shandong, China.
（+86）535-3573511
Official WeChat